External Grants by School/Department

Organized by Department/Division, then lists name of PI, Grant/Contract Title, Sponsor and Amount.

Anesthesiology

Yun Xia GDNF in the enteric nervous system Nat In Diabetes & Digestive & KidneyDiseases $131,193

Biomedical Informatics

Umit Catalyurek Clustering streaming graph data Univ of California $88,668
Daniel Janies Novel analytical and empirical approaches to the origin and prediction of pathogenicity Am Museum of Natural History $212,650
Joel Saltz CaBIG architechture workspace-CaGRID developer (task2) Booz Allen Hamilton Inc $306,475
Joel Saltz caBIG architecture workspace Booz Allen Hamilton Inc $92,380
Joel Saltz caBIG architecture: Task 3 caGRID developer project Booz Allen Hamilton Inc $458,945
Joel Saltz caBIG Task 4: Strategic planning strategic level working group participation Booz Allen Hamilton Inc $37,250
Joel Saltz Center for grid-enabled medical image analysis. Nat In Biomedical Imaging & Bioengineering $519,228
Joel Saltz CSR - AES: Collaborative research: Intelligent design and optimization of parallel and distributed applications Nat Science Foundation $49,999
Joel Saltz Scalable grid technologies for grid service Kitware, Inc $76,919

Comprehensive Cancer Center

Carolina Bonilla Interrogating chromosome 12 for prostate cancer susceptibility genes in African Americans using an admixture mapping approach Army $123,711
Laura Rush Aberrant DNA methylation in acute myeloid leukemia. Nat Cancer Inst $117,593
Lianhui Tao Modulation by chemoprevention agents of DNA demethylase and hypomethylation Nat Cancer Inst $74,750
Lizhao Wu Tumor suppressor and oncogenic pathways in the placenta. Nat Cancer Inst $88,754

Emergency Medicine

Jeffrey Caterino Validation of an innovative approach to error reduction Massachusetts General Hospital $3,722
Thomas Gavin Endotracheal intubation skills of EMT basics OH Dept of Public Safety $42,404
Robert Guthrie A randomized, double-blind, placebo controlled, forced titration Phase IV study comparing telmisartan 80 mg + hydrochlorothiazide 25 mg versus valsartan 160 mg + hydrochlorothiazide 25 mg ... Boehringer Ingelheim Pharmaceuticals Inc $24,032
Robert Guthrie Safety and efficacy of muraglitazar in combination with metformin compared to glimepiride in combination with metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin therapy alone Bristol-Myers Squibb Co $13,296
Brian Hiestand Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidlines: The CRUSADE national quality initiative Duke Univ $1,460
Brian Hiestand CRUSADE: Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines. Duke Univ $1,380
Michael Sayre Comparison of airway management techniques in brain-injured hypotensive trauma patients OH Dept of Public Safety $44,372
Michael Sayre Induction of mild hypothermia in resuscitated cardiac arrest patients using traditional cooling techniques vs. the Medivance Arctic Sun Temperature Management System Medivance, Inc $5,318

Family Medicine

Thomas Best In-situ low load mechanical behavior of skeletal muscle: An improved understanding of injury and healing NSF DIV BIOENGINEERING & ENVIRONMENTAL $38,642
Lawrence Gabel Ohio TeleHealth, Education & Linkage Program (Ohio TeleHELP): A proof-of-concept study OH Board of Regents $150,000
Douglas Knutson Pre-doctoral training in primary care (Teaching to the CORE) Health Resources & Services Admin $208,020
William Miser A double-blind, randomized, controlled, multicenter study to evaluate the safety, tolerability and immunogenicity of a refrigerator-stable formulation of Zoster vaccine live. PEDIATRIC CLINICAL TRIALS INTERNATIONAL $1,831
William Miser A multicenter randomized, double-blind study to evaluate the safety and efficacy of MK-0431 monotherapy in patients with type 2 diabetes mellitus who have inadequate glycemic control PEDIATRIC CLINICAL TRIALS INTERNATIONAL $3,979
William Miser A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose finding study evaluating the safety and efficacy of infliximab administration in symptomatic subjects with moderate to severe COPD. PEDIATRIC CLINICAL TRIALS INTERNATIONAL $809
William Miser Bioterrorism training and curriculum development program (BTCDP). Health Resources & Services Admin $415,151
William Miser Effect of slow digesting carbohydrate (SDC) formula on glycemic response in patients with type II diabetes PEDIATRIC CLINICAL TRIALS INTERNATIONAL $23,352
Douglas Post Efficacy of web-based training in skin cancer triage. Rhode Island Hosp $55,792
Douglas Post Patient-centered communication during chemotherapy Nat Cancer Inst $108,990
Douglas Post Risky sexual behavior and cervical cancer in rural Ohio women Am Cancer Soc-Ohio $30,000
Maryjo Welker Academic administration units in primary care. Bur of Health Professions $236,520
Randell Wexler Cognitive behavioral therapy techniques and lifestyle changes: Reducing systolic blood pressure AM ACADEMY OF FAMILY PHYSICIANS FDN $19,069

Department of Internal Medicine

Division of Cardiovascular Medicine

William Abraham A CHF trial investigating outcomes of exercise training Duke Univ $3,075
William Abraham ACTION - A CHF trial investigating outcomes of exercise Nat Heart, Lung, & Blood Inst $135,731
William Abraham IHM system technology assessment study. Medtronic Inc $750
William Abraham InSync(TM) post market registry. Medtronic Inc $2,115
William Abraham Management of patients advanced signs and symptoms of heart failure (COMPASS-HF). Medtronic Inc $119,170
William Abraham Medtronic Model 7279 InSync III Marquis ICD cardiac resynchronization system investigational plan Medtronic Inc $2,700
William Abraham Organized program to initiate life-saving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). GlaxoSmithKline $4,750
William Abraham Paracor ventricular support system Paracor Medical, Inc $0
Gunjan Agarwal Myocardial matrix remodeling by DDRs Nat Heart, Lung, & Blood Inst $69,468
Gunjan Agarwal Regulation of myocardial fibrosis by discoidin domain receptors American Heart Association $32,500
Barbara Alevriadou Reperfusion-induced endothelial cell dysfunction Nat Heart, Lung, & Blood Inst $149,500
Philip Binkley An open label enoximone extension study for subjects who clinically deteriorate during the enoximone withdrawal phase of EMPOWER Myogen Inc $5,100
Philip Binkley Eliminating barriers to effective training in clinical investigation Nat Center for Research Resources $669,785
Philip Binkley Enoximone plus extended-release metoprolol succinate in subjects with advanced chronic heart failure (EMPOWER) - a phase III, randomized, double-blind, double placebo-controlled, multicenter, three parallel group study of enoximone plus extended-release Myogen Inc $4,351
Philip Binkley Evaluation of intravenous levosimendan efficacy versus placebo in the short term treatment of decompensated chronic heart failure. Abbott Labs $7,706
Philip Binkley Follow-up serial infusions of natrecor (nesiritide) for the management of patients with heart failure FUSION II. Scios Inc $11,976
Philip Binkley Study of oral enoximone versus placebo in advanced chronic heart failure subjects. Myogen Inc $23,212
Philip Binkley The impact of ultrafiltration versus standard IV diuretic therapy on heart rate variability in congestive heart failure CHF Solutions, Inc $47,195
Glen Cooke Pharmacogenetic antiplatelet strategies in CHD patients Nat Heart, Lung, & Blood Inst $133,992
Curt Daniels A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in patients wth mildly symptomatic pulmonary arterial hypertension Actelion Clinical Operations, Inc $2,000
David Feldman Predictors of responses to CRT version 1 Medtronic Inc $7,026
David Feldman Resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) Medtronic Inc $19,221
Nicholas Flavahan Alpha2C adrenergic receptors and cutaneous circulation Nat Heart, Lung, & Blood Inst $336,375
Nicholas Flavahan Efficacy, tolerability, and biology of Rho-kinase inhibitor (Fasudil) in the treatment of Raynaud's phenomenon Peninsula Community Fdn $83,952
Nicholas Flavahan Mechanisms of accelerated graft arteriosclerosis. Johns Hopkins Univ $98,017
Nicholas Flavahan Mechanisms of vascular dysfunction in vibration injury Nat Inst Occupational Safety & Health $261,625
Nicholas Flavahan Redox regulation of arteriole function Nat Heart, Lung, & Blood Inst $331,875
Nicholas Flavahan Vascular dysfunction in scleroderma. Scleroderma Federation Inc $40,000
Garrie Haas A phase 2, randomized, double blind, parallel-group, placebo-controlled, multicenter study to examine the effects of AC2592 administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure Amylin Corp $0
Garrie Haas A prospective evaluation of closed-loop stimulation in heart failure patients (HF-CLS). Biotronik Inc $5,766
Garrie Haas Fluid accumulation status trial (FAST). Medtronic Inc $2,450
Garrie Haas Hemodynamically guided home self-therapy in severe heart failure patients (HOMEOSTASIS II) Savacor, Inc $0
Garrie Haas MOMENTUM: Multicenter trial of the Orqis Medical CRS for the enhanced treatment of CHF unresponsive to medical therapy ORQIS MEDICAL $25,132
Garrie Haas Multi-center, double-blind, placebo controlled, parallel group, multiple dose study of DITPA in patients with NYHA class III and IV congestive heart failure who have low serum T3 levels Titan Pharmaceuticals, Inc $0
Garrie Haas Resynchronization therapy in normal QRS study (RethinQ) St. Jude Medical Co $0
Garrie Haas Safety and tolerability of IV PST 2744 in adults with chronic heart failure: A phase I/II study Sigma-Tau Healthscience SPA $31,413
Garrie Haas SK & F-105517/369: An open nonrandomized comparison of pharmacokinetic profiles of carvedilol MR and IR on repeat dosing in chronic CHF patients and survivors of an acute MI and LVD GlaxoSmithKline $147,308
Guanglong He Electron paramagnetic resonance imaging of the redox status and oxygenation of the in vivo rat heart American Heart Association $65,000
Guanglong He In vivo EPR imaging of myocardial oxygen consumption Nat Heart, Lung, & Blood Inst $322,456
Govindasamy Ilangovan Microxymetry techniques for cardiomyocyte respiration Nat In Biomedical Imaging&Bioengineering $186,875
Periannan Kuppusamy Conference/workshop on EPR spectroscopy and imaging Nat In Biomedical Imaging&Bioengineering $10,000
Periannan Kuppusamy Development of spin probes for cell-tagging and oximetry Nat In Biomedical Imaging&Bioengineering $269,101
Periannan Kuppusamy In vivo EPR imaging and redox status and thiols in tumor. Nat Cancer Inst $306,475
Periannan Kuppusamy Novel methods for in vivo imaging of tissue oxygenation Nat In Biomedical Imaging&Bioengineering $269,100
Haitao Li Characterization of the molecular mechanism of organic nitrates bioactivation Am Heart Assn-Ohio Affiliate Inc $60,500
Haitao Li Induction of cellular antioxidants and cardioprotection Nat Heart, Lung, & Blood Inst $404,707
Zhenguo Liu Asymptomatic AF and stroke evaluation in pacemaker patients and the AF reduction atrial pacing trial St. Jude Medical Co $0
Zhenguo Liu Effects of nitric oxide on stem cell differentiation Nat Heart, Lung, & Blood Inst $132,624
Charles Love AV-node ablation with CLS and CRT pacing therapies for the treatment of symptomatic AF (AVAIL CLS/CRT) Biotronik Inc $0
Charles Love Evaluation of the safety and efficacy of the OPTIMIZER II system with active fixation leads in subjects with heart failure resulting from systolic dysfunction: FIX-HF-5. Impulse Dynamics, Inc $12,785
Charles Love Home monitoring technology for ICD therapy (WAMMI). Biotronik Inc $5,500
Charles Love OPTION CRT/ATx cardiac resynchronization therapy and atrial therapy. Biotronik Inc $15,450
Charles Love Resynchronization hemodynamic treatment for heart failure management study (RHYTHM ICD). St. Jude Medical Co $600
Charles Love Study for atrial fibrillation reduction (SAFARI) Vitatron Inc $200
Raymond Magorien A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary intervention/TIMI-38 Quintiles Transnational Corp $0
Raymond Magorien Cobalt chromium stent with antiproliferative for restenosis II trial Conor Medsystems, Inc $0
Raymond Magorien D.E.S.cover registry. Cordis Corp $11,900
Raymond Magorien Double-blind, randomized comparator-controlled study in subjects with type 2 diabetes mellitus comparing the effects of pioglitazone HCl versus glimepiride on the progression of coronary atherosclerotic disease as measured by intravascular... TAKEDA PHARMACEUTICALS INC $20,865
Raymond Magorien Occluded artery trial. NY UNIVERSITY $925
Raymond Magorien Strategy to reduce atherosclerosis development involving administration of rimonabant - the intravascular ultrasound study (STRADIVARIUS) Sanofi-Synthelabo Inc $6,000
Raymond Magorien The ACUITY trial: A randomized comparison of Angiomax(R) (bivalirudin) versus Lovenox(R) (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation, Protocol No. TMC-BIV-02-08. Medicines Co, The $32,350
Raymond Magorien Trial to assess chelation therapy (TACT). MOUNT SINAI MEDICAL CENTER $11,500
David Orsinelli A phase IV open-label, randomized, multi-center exercise stress trial to examine the effectiveness of Definity (R) and evaluate the predictive value of contrast stress echocardiography in patient outcomes. Bristol-Myers Squibb Co $31
Subha Raman Comparison of noninvasive CT angiography for epicardial coronary imaging with catheter-based angiography (CINEMA). Duke Univ $8,800
Subha Raman Iron and atherosclerosis Nat Heart, Lung, & Blood Inst $201,825
Subha Raman Paracor ventricular support system core lab Paracor Medical, Inc $4,000
Yong Xia Superoxide generation from endothelial NO synthase. Nat Heart, Lung, & Blood Inst $299,000
Jay Zweier Dithiole-thiones and -ones: Chemistry to Biochemistry. Univ of Maryland $92,829
Jay Zweier In vivo EPR/NMR co-imaging of free radicals Nat In Biomedical Imaging&Bioengineering $827,358
Jay Zweier Measurement of free radical generation in the heart Nat Heart, Lung, & Blood Inst $333,022
Jay Zweier Oxygen radicals and nitric oxide in postischemic injury Nat Heart, Lung, & Blood Inst $479,275
Jay Zweier Proton electron double resonance imaging (PEDRI) of free radicals Nat In Biomedical Imaging&Bioengineering $731,359
Jay Zweier The development of new functional nitroxide probes for noninvasive EPR spectroscopy and imaging Civilian Res & Dev Fdn $12,390

Division of Endocrinology, Diabetes and Metabolism

Rebecca Jackson Clinical Center for the Clinical Trial and Observational Study of the Women's Health Initiative. Nat Heart, Lung, & Blood Inst $608,768
Rebecca Jackson Clinical centers for the osteoarthritis initiative. Nat In Arthritis&Muscoskeletal&Skin Ds $2,619,681
Rebecca Jackson Fat reduction, HRT use and benign breast disease risk. Yeshiva Univ $24,269
Rebecca Jackson WHI ancillary - Mammographic density in invasive breast cancer Univ of North Carolina $3,000
Rebecca Jackson Women's Health Initiative memory study Wake Forest Univ $22,757
Rebecca Jackson Women's Health Initiative sex hormone and genetic risk factors for hip fracture California Pacific Medical Center $24,307
Rebecca Jackson Women's health initiative study of cognitive aging. Wake Forest Univ $22,815
Lawrence Kirschner Carney complex: a model for PKA-mediated tumorigenesis. Nat Cancer Inst $511,981
Lawrence Kirschner Protein kinase a and its role as a mediator of both nf1 and nf2-associated Schwann cell tumorigenesis. Army Medical Res & Materiel Command $100,000
Richard Kloos A phase 1, open label, dose escalation safety study of thyrogen in patients with non-toxic multinodular goiter Genzyme Corp $1,730
Kwame Osei A multicenter, randomized, double-blind study to evaluate the safety and efficacy of the addition of MK-0431 to patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone therapy Merck & Co Inc $3,370
Kwame Osei An open-label study to examine the long-term effect on glucose control (HbA1c) and safety and tolerability of Exenatide given two times a day to subjects with type 2 diabetes mellitus. Amylin Corp $888
Kwame Osei BARI II: Revascularization and glycemic control in NIDDM. Univ of Pittsburgh $15,025
Kwame Osei Compare the efficacy and safety of NovoLog Mix 70/30 BID in combination with metformin and pioglitazone to metformin and pioglitazone alone in insulin naive subjects with type 2 diabetes Novo Nordisk Pharmaceuticals $4,020
Kwame Osei Duloxetine versus placebo in the treatment of patients with painful diabetic neuropathy. Eli Lilly & Co $1,100
Kwame Osei Mechanisms of pro-thrombosis in diabetes mellitus (an ancillary substudy of the Bypass Angiography Revascularization Investigation in Type 2 Diabetes (BARI 2D) Study) UNIV OF VERMONT $13,426
Kwame Osei NNC61-0029 in type 2 diabetes. Novo Nordisk Pharmaceuticals $2,000
Kwame Osei Outcome reduction with initial glargine intervention (the ORIGIN trial). Aventis Pharm Prods $21,000
Kwame Osei Prevention of cardiovascular disease in diabetes mellitus-clinical center network. Case Western Reserve Univ $731,143
Kwame Osei Primary prevention of type 2 diabetes and cardiovascular risks in African Americans: Role of A1C and adipocytokines Eli Lilly & Co $0
Kwame Osei Safety and efficacy of pioglitazone HCl or glyburide in subjects with type 2 diabetes naive to pharmacologic therapy. PPD Dev $7,068
Kwame Osei Safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes with impaired glucose tolerance. Novartis Pharmaceuticals Corp $6,140
Kwame Osei Study of the long-term safety of pramlintide acetate in subjects with type 1 diabetes mellitus completing protocol 137-150. Amylin Corp $2,127
Matthew Ringel Akt intracellular localization in thyroid cancer Nat Cancer Inst $265,736
Matthew Ringel AKT1 and p27 in progressive thyroid cancer Am Cancer Soc Inc $90,000
Matthew Ringel Anti-metastatic effect of MCIP1 in thyroid cancer Nat Cancer Inst $128,570
Fred Sanfilippo, William Malarkey General clinical research center. Nat Center for Research Resources $83,388
Dara Schuster External continuous subcutaneous infusion of insulin aspart (NovoLog) versus insulin lispro (Humalog): An open-label, randomized, parallel group, multicenter study in children and adolescents with type 1 diabetes Novo Nordisk Pharmaceuticals $17,137

Division of General Internal Medicine

Cynthia Ledford OSU faculty development for underserved communities Health Resources & Services Admin $167,536
Catherine Lucey Resident faculty practicum in practice-based learning and improvement Am Board of Internal Medicine Fdn $13,674

Division of Hematology and Oncology

Belinda Avalos-Copelan The G-CSF receptor and ubiquitination Department of Health & Human Services $186,876
Tanios Bekaii-Saab A dose escalating (phase l) study looking at the biomodulation of capecitabine by docetaxel and gemcitabine in patients with advanced pancreas cancer Nat Comprehensive Cancer Network $132,881
Tanios Bekaii-Saab A phase I dose escalation and biological study of capecitabine and mitomycin-C (MMC) in patients with gastrointestinal solid malignancies Roche Labs, Inc $24,000
Tanios Bekaii-Saab A phase I dose escalation study of capecitabine, carboplatin and weekly paclitaxel and a phase II trial of the combination in patients with adenocarcinoma of unknown primary site Roche Labs, Inc $2,500
Tanios Bekaii-Saab A phase II study of capecitabine and docetaxel in previously untreated advanced non-small cell lung cancer patients Roche Labs, Inc $18,472
Tanios Bekaii-Saab An observational study of avastin (bevacizumab) in combination with chemotherapy for first-line treatment of metastatic colorectal adenocarcinoma Genentech Inc $16,100
Tanios Bekaii-Saab OSU 0445: A randomized, open label, phase II study of OSI-7904L versus 5-FU/LV as first-line treatment in patients with unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract OSI Pharmaceuticals, Inc $0
Tanios Bekaii-Saab OSU 0447: A phase II study of efficacy and tolerability of GW572016 in patients with advanced hepatocellular and biliary carcinomas GlaxoSmithKline $0
Tanios Bekaii-Saab OSU 0447: Efficacy and tolerability of GW 572016 in patients with advanced hepatocellular and biliary carcinomas Sci Applications Intl Corp $76,704
Tanios Bekaii-Saab OSU 05018: A randomized, open-label, controlled, clinical trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of subjects with metastatic colorectal cancer Immunex Corp $0
Clara Bloomfield CALGB Foundation protocol capitation projects 1997 Cancer & Leukemia Group B Fdn $40,352
Clara Bloomfield CALGB Univ Chicago protocol capitation projects 1998. Univ of Chicago $137,659
Clara Bloomfield CALGB University of Chicago services agreement. Univ of Chicago $6,314
Clara Bloomfield Cancer and Leukemia Group B - The Ohio State University. Nat Cancer Inst $380,084
Kristie Blum CALGB 50303: Phase III study of R-CHOP v. dose-adjusted EPOCH-R with molecular profiling in untreated de novo diffuse large B-cell lymphomas. Univ of Chicago $120,000
Kristie Blum Dual targeting of NF-kB and Akt survival pathways in non-Hodgkin's lymphoma. Cancer & Leukemia Group B Fdn $44,000
Kristie Blum OSU 0442: A phase II study of clofarabine in patients with aggressive non-Hodgkin's lymphoma ILEX Oncology $22,013
Kristie Blum Targeting transcriptional repression in CLL Nat Cancer Inst $135,076
William Blum Pharmacokinetic supplement to NCI Study CALGB C9710: A Phase IV commitment (OSU 0438). Cephalon Inc $7,103
William Blum Phase I study of arsenic trioxide in combination with valproic acid in patients with myelodysplasia. Cell Therapeutics Inc $19,963
John Byrd A phase I/II study of lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab in subjects with relapsed chronic lymphocytic leukemia. Biogen IDEC Inc $112,187
John Byrd B-CLL biology: Impact of combination chemotherapy. Mayo Fdn $718,552
John Byrd Chronic lymphocytic leukemia research consortium-nursing salary support. Univ of California at San Diego $26,655
John Byrd Combined ritsuimab w/high dose methylprednisolone for treatment of CLL and PLL. Univ of California at San Diego $34,785
John Byrd Epigenetic targeted therapy for chronic lymphocytic leukemia Nat Cancer Inst $306,475
John Byrd Etanercept and rituximab in patients with chronic lymphocytic leukemia and small cell lymphocytic lymphoma. Genentech Inc $15,000
John Byrd Feasibility/phase II trial of fludarabine, rituximab, and alemtuzumab for previously treated B-chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)(0404) Berlex Labs Inc $15,000
John Byrd Feasibility/phase II trial of fludarabine, rituximab, and campath-1H for previously un-treated B-chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0404) Genentech Inc $9,000
John Byrd Hu1D10 in CLL: Clinical and laboratory studies. Nat Cancer Inst $306,290
John Byrd Humanized HLA-DR antibody mechanism validation and human tissue sampling Kirin Brewery Co, Ltd $61,000
John Byrd Leukemia and Lymphoma Society Scholar in clinical research grant. Leukemia & Lymphoma Soc $200,000
John Byrd Molecular markers: response to chemo-immunotherapy in CLL Nat Cancer Inst $269,520
John Byrd OSU 0388 A CRC Phase II study of subcutaneous Campath-1H in patients with B-cell chronic lymphocytic leukemia and residual disease after chemotherapy Berlex Labs Inc $0
John Byrd OSU 05008: A phase I, open-label, dose-escalation trial of anti-CD40 monoclonal antibody (CHIR12.12) administered intravenously to subjects with advanced chronic lymphocytic leukemia that is refractory or relapsed after prior treatment Chiron Corp $38,780
John Byrd Phase II trial of motexafin gadolinium (MGd) in patients with relapsed or refractory chronic lymphocytic leukemia. Pharmacyclics Inc $3,300
John Byrd Specialized Center of Research; Experimental therapeutics in CLL. Leukemia & Lymphoma Soc $1,250,000
John Byrd Study of etanercept and rituximab in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Immunex Corp $57,500
John Byrd Study of MDX-06 administered weekly for 4 weeks in patients with refractory/relapsed CD30 positive lymphoma. Medarex Inc $11,257
John Byrd Trial of cyclosphosphamide, pentostatin and rituximab for previously untreated B-chronic lymphocytic leukemia. Supergen Inc $55,000
Michael Caligiuri CALGB 10102 - Flow Cytometry Cancer & Leukemia Group B Fdn $11,583
Michael Caligiuri CALGB leukemia tissue bank suppplement Univ of Chicago $428,144
Michael Caligiuri Cancer and leukemia group B - leukemia correlative science Nat Cancer Inst $1,053,278
Michael Caligiuri Elucidation of the partial tandem duplication of MLL in acute leukemia. Lady Tata Memorial Trust $29,400
Michael Caligiuri Functional characterization of MLL gene fusions. Nat Cancer Inst $504,450
Michael Caligiuri Generation of CD 16 NK cell line Xencor, Inc $7,500
Michael Caligiuri IL-15 characterization through experimental immunology. Nat Cancer Inst $285,919
Michael Caligiuri Innate immunity: Elucidation/modulation - cancer therapy. Nat Cancer Inst $1,925,557
Michael Caligiuri Oncology training grant. Nat Cancer Inst $446,877
Michael Caligiuri Prevention of post-transplant lymphoproliferative disorder Leukemia & Lymphoma Soc $200,000
Michael Caligiuri The Ohio State University comprehensive cancer support grant. Nat Cancer Inst $4,295,336
Michael Caligiuri Tolerability and pharmacokinetics/pharmacodynamics of multiple oral doses of CT53518 in patients with acute myelogenous leukemia. Millennium Pharmaceuticals Inc $16,000
Spero Cataland OSU 05053: An open label, safety and tolerability study of deferasirox for treatment of transfusional iron overload in low-risk and INT-1, myelodysplastic patients using serum ferritin monitoring Novartis Pharmaceuticals Corp $0
Spero Cataland Phase II study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 10 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Novartis Pharmaceuticals Corp $10,443
Jeffrey Chalmers Continuous cell sorting by magnetophoresis Cleveland Clinic Fdn $18,933
Jeffrey Chalmers High performance magnetic cell sorting. Nat Cancer Inst $340,225
Jeffrey Chalmers Magnetic separation of liberated islets during isolation Nat In Diabetes&Digestive&KidneyDiseases $52,788
Jeffrey Chalmers Portable biochip for rapid detection of biowarfare agents Cleveland Clinic Fdn $25,674
Steven Clinton A prospective study of diet and prostate cancer; project one Harvard Univ $240,163
Steven Clinton A prospective study of diet and prostate cancer; project three Harvard Univ $118,852
Steven Clinton Calcium and vitamin D interactions in prostate carcinogenesis Am Inst for Cancer Res $165,000
Steven Clinton Phase II chemoprevention trial of selenium and prostate cancer. Univ of Arizona $591
Steven Clinton SWOG (Southwest Oncology Group) prostate cancer prevention trial Cancer Therapy & Res Fdn of South Texas $3,550
Steven Clinton SWOG (Southwest Oncology Group) selenium and vitamin E cancer prevention trial - SELECT Cancer Therapy & Res Fdn of South Texas $6,950
Steven Clinton Tomato-soy juice for prostate cancer Nat Cancer Inst $191,921
Steven Clinton Vitamin D status and prostate cancer Purdue Univ $352,777
Charles Eisenbeis Daily low-dose IL-2 augments anti-CD20 antibody therapy. Nat Cancer Inst $134,784
Charles Eisenbeis Rituximab in combination with recombinant human IL-2 for relapsed low-grade or follicular non-Hodgkin's lymphoma in subjects who have previously failed rituximab. Chiron Corp $34,350
Sherif Farag CALGB 100101 - Flow Cytometry Cancer & Leukemia Group B Fdn $18,750
Sherif Farag mTOR inhibition as a therapeutic target in myeloma. Nat Cancer Inst $269,100
Sherif Farag OSU 04101: A phase I dose escalation trial of Velcade(R) in conjunction with high-dose melphan for autologus peripheral blood stem cell transplantation followed by Velcade(R) post-transplant maintenance therapy in patients with multiple myeloma Millennium Pharmaceuticals Inc $0
Sherif Farag Phase I/II trial of pegylated liposomal doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in combination with Arsenic Trioxide (Trisenox (R)) in untreated patients with symptomatic multiple myeloma Cell Therapeutics Inc $20,000
Sherif Farag Phase II trial of pegylated liposomal doxorubicin (Doxil), vincristine, and dexamethasone (DVd) in combination with arsenic trioxide (Trisenox (R)) in untreated patients with symptomatic multiple myeloma. Ortho Biotech Prods LP $35,003
Sherif Farag QMS technology to deplete T cell alloreactivity. Nat Inst of Allergy &Infectious Diseases $377,631
Sherif Farag Specific immunotherapy, compared to non-specific immunotherapy, in patients with non-Hodgkin's lymphoma. Genitope Corp $9,780
Michael Grever CALGB 100101 - PK analyses (a phase II trial of intravenous Pentostatin for the treatment of patients with refractory chronic graft-versus-host disease) Cancer & Leukemia Group B Fdn $7,750
Michael Grever Phase I trials of anticancer agents. Nat Cancer Inst $604,449
Kari Kendra A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high dose IL-2 vs. high dose IL-2 alone in patients with metastatic melanoma (OSU 0351) Chiron Corp $4,000
Kari Kendra A randomized phase II study comparing gemcitabine/trastuzumab vs. gemcitabine/cisplatin/trastuzumab in patients with metastatic breast cancer Eli Lilly & Co $23,000
Rebecca Klisovic OSU 05055 A phase I study of MLN518 given in combination with standard induction chemotherapy for the treatment of patients with newly diagnosed acute myelogenous leukemia Millennium Pharmaceuticals Inc $0
Rebecca Klisovic OSU 05071: A randomized two by two, multicenter, open-label phase II study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL+ chronic myelogenous leukemia who are resistant or intolerant to imatinib mesylate Bristol-Myers Squibb Co $0
Rebecca Klisovic OSU 05072: Study of BMS-354825 administered orally in subjects with CML in accelerated phase or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive ALL who are resistant or intolerant to imatinib mesylate Bristol-Myers Squibb Co $0
Eric Kraut Cascade hemophilia consortium. Cascade Hemophilia Fdn $132,500
Eric Kraut DHHS/MCHB-Region V-east hemophilia comprehensive care network. Hemophilia Fdn of Michigan $26,857
Eric Kraut HIPP Program - Adult hemophilia insurance premium payment program. OH Dept of Health $30,250
Eric Kraut HTRS Registry The Hemophilia & Thrombosis Research Soc $8,850
Eric Kraut Liposome encapsulated SN38 (LE-SN38) in patients with advanced cancer. Neopharm Inc $59,118
Eric Kraut Region V-east hemophilia comprehensive care network - CDC Award. Hemophilia Fdn of Michigan $43,949
Laura Kresty Intermediate surrogate biomarker studies in squamous cell carcinoma wa#13 n01 cn43308 Washington Univ $415,714
Laura Kresty Reversing epigenetic changes through HDAC inhibition: a tool for cancer prevention Ohio Cancer Res Assoc $24,970
Thomas S Lin A novel dosing schedule of flavopiridol in CLL Nat Cancer Inst $295,263
Thomas S Lin A phase 1 study of the AKT inhibitor 17-AAG in CLL Nat Cancer Inst $295,263
Thomas S Lin A phase II study of xcellerated T cells (TM) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma. Xcyte Therapies, Inc $22,540
Thomas S Lin Monoclonal antibody therapy in B-Cell CLL. Nat Cancer Inst $131,814
Thomas S Lin OSU 04115: A phase I open-label dose-finding study to evaluate the safety, pharmacokinetics and pharmacodynamics of AMG 623 in subjects with B-cell CLL relapsed or refractory to purine nucleoside treatment Amgen Inc $16,700
Thomas S Lin OSU 04116: Phase II trial of FavId and GM-CSF in subjects who demonstrated progressive disease and did not receive FavId on study FavId-06 Favrille Inc $2,500
Thomas S Lin OSU 0461: Phase III, randomized, double blind placebo-controlled trial of FavID and GMCSF following rituximab in subjects with follicular B-cell non-Hodgkins lymphoma Favrille Inc $38,827
Thomas S Lin OSU 0467: Phase II trial of motexafin gadolinium (MGd) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with refractory or relapsed disease Pharmacyclics Inc $7,000
Thomas S Lin Trial of Rituxan (R) plus FavId (TM) and GM-CSF immunotherapy in patients with grade 1 or 2 follicular B-cell lymphoma. Favrille Inc $20,897
Richard Love Adjuvant hormonal therapy in Vietnamese breast cancer Nat Cancer Inst $383,248
Richard Love Luteal adjuvant oophorectomy in Vietnamese breast cancer Nat Cancer Inst $568,493
David Lucas Correlative laboratory studies Berlex Labs Inc $80,000
Guido Marcucci LARG, a novel leukemia-associated guanine exchange factor. Nat Cancer Inst $132,516
Guido Marcucci Pharmacologic modulation of chromatin remodeling in leukemia Nat Cancer Inst $252,449
Guido Marcucci Pharmacological modulation of epigenetic changes in AML. Nat Cancer Inst $303,674
Guido Marcucci Pharmacological modulation of epigenetic mutations and chromatin remodeling in acute myeloid leukemia. Cancer & Leukemia Group B Fdn $44,000
J Paul Monk III A phase I study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin(R)) in patients with advanced solid tumors. Kosan Biosciences Inc $177,091
Thomas Olencki OSU 05029: Phase III randomized, placebo-controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable Stage III or Stage IV melanoma Onyx Pharmaceuticals, Inc $17,330
Gregory Otterson A phase II, randomized, open-label study of single agent CI-1033 in patients with advanced non-small cell lung cancer. Pfizer Inc $74,630
Gregory Otterson Epigenetic changes in mesothelioma Mesothelioma Applied Research Fdn $50,000
Gregory Otterson OSU 04104: A phase 2 study to evaluate the efficacy and safety of palifermin in the reduction of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for locally advanced non-small cell lung cancer (NSCLC) Amgen Inc $9,375
Gregory Otterson OSU 05056: A multicenter, open-label, phase 2 study of Velcade for injection in previously treated patients with stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features Millennium Pharmaceuticals Inc $6,686
Gregory Otterson Phase I-II study of inhaled doxorubicin (doxorubicin HCl inhalation solution), Resmycin (TM) plus IV docetaxel and cisplatin in patients with locally advanced or metastatic unresectable non-small cell lung cancer. Zivena Inc $98,967
Gregory Otterson Synchronicity: A study to evaluate the effectiveness of Aranesp (R) at 300 mcg Q3W on clinical outcomes in cancer patients with anemia due to chemotherapy. Amgen Inc $6,600
Michael Pereira Chemoprevention of tobacco-related cancer in animals. Nat Cancer Inst $158,235
Michael Pereira Preclinical efficacy and intermediate biomarker assays Nat Cancer Inst $48,652
Pierluigi Porcu An open label study of ONTAK to estimate response in cutaneous T-cell lymphoma study Tufts-New England Medical Ctr $3,775
Pierluigi Porcu Combined cytokine-monoclonal antibody therapy in lymphoma. Nat Cancer Inst $135,513
Pierluigi Porcu Phase I study of CHOP plus humanized anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) in previously untreated T/NK-cell lymphomas and CD20-negative large B-cell lymphomas. Berlex Labs Inc $25,000
Pierluigi Porcu Rituximab in combination with recombinant human IL-2 for relapsed low-grade or follicular non-Hodgkin's lymphoma. Chiron Corp $7,688
Chris Rhoades OSU 0482: A phase II study of pemetrexed chemotherapy in poor-risk patients with advanced head and neck cancer Eli Lilly & Co $16,200
Manisha Shah A phase III, randomized, double-blind, placebo-controlled study of SU011248 in the treatment of patients with imatinib mesylate-resistant or intolerant malignant gastrointestinal stromal tumor. Pfizer Inc $163,612
Manisha Shah OSU 0471: Open-label phase 2 clinical trial of bi-weekly dosing of irofulven plus capecitabine in patients with either anaplastic or locally advanced/metastatic differentiated thyroid cancer MGI Pharma Inc $37,224
Manisha Shah Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. Nat Comprehensive Cancer Network $45,146
Manisha Shah Targeting RAF and VEGF signaling in thyroid cancer Nat Cancer Inst $201,514
Charles Shapiro A phase III trial of novel epothilone BMS-247550 plus capacitabine versus capecitabane alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane. (0393) Bristol-Myers Squibb Co $3,563
Charles Shapiro An open label phase I study of humanized milk fat globule-1 antibody in patients with locally advanced or metastatic breast cancer (TOPCAT) HOFFMANN-LAROCHE INC $16,519
Charles Shapiro CALGB chair support, symptom intervention subcommittee Univ of Chicago $30,900
Charles Shapiro Capecitabine in combination with weekly docetaxel in metastatic breast cancer. Aventis Pharm Prods $40,000
Charles Shapiro CPT-11 and mytomycin-C (MMC) in metastatic breast cancer. Pharmacia & Upjohn Inc $24,600
Charles Shapiro OSU 0450: Phase II randomized adjuvant trial of dose-dense docetaxel before and after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast cancer BridgeSite Clinical Research, Inc $95,909
Charles Shapiro OSU0494: Phase II trial of exemestane (Aromasin) in combination with fluvestrant (Faslodex) in postmenopausal women with hormone responsive advanced breast cancer Pfizer Inc $33,600
Charles Shapiro Phase II randomized open label study of Letrozole in combination with two dose levels and schedules of oral CCI-779, or Letrozole alone, in postmenopausal women with locally advanced or metastatic breast cancer. WYETH PHARMACEUTICALS INC $8,281
Charles Shapiro Phase II study of bevacizumab in combination with docetaxel in patients with advanced breast cancer Genentech Inc $42,000
Charles Shapiro Phase II study of sequentially administered mitomycin and irinotecan in patients with refratory metastatic and inflammatory breast cancers - molecular correlative studies. Nat Comprehensive Cancer Network $46,285
Charles Shapiro Study of bevacizumab in combination with docetaxel in patients with advanced breast cancer. Aventis Pharm Prods $45,637
Charles Shapiro Study of capecitabine in combination with weekly docetaxel in metastatic breast cancer. Roche Labs, Inc $89,000
Charles Shapiro Study of two dose levels of ERA-923 for the treatment of metastatic breast cancer in postmenopausal women who have failed tamoxifen therapy. Genetics Inst, Inc $26,600
Gary Stoner Prevention of esophageal cancer with berries. Nat Cancer Inst $469,843
Gary Stoner Tobacco carcinogenesis and chemoprevention - Project #4 - P01 CA070972 Pennsylvania State Univ $31,977
Miguel Villalona A phase 2 study of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer who have progressed following initial therapy for advanced or metastatic disease. Kosan Biosciences Inc $35,191
Miguel Villalona A randomized phase II study of single agent erlotinib (Tarceva (TM), OSI-774) versus standard chemotherapy in patients with previously untreated advanced NSCLC and a poor performance status. OSI Pharmaceuticals, Inc $7,280
Miguel Villalona Biomodulation of capecitabine by docetaxel in non-small cell lung cancer. Nat Cancer Inst $306,475
Miguel Villalona OSU 0443: A phase II randomized study of OSI-774 in African-American patients with advanced and previously treated non-small cell lung cancer Genentech Inc $0
Miguel Villalona OSU 0474: A phase I, open label, dose escalation study of weekly dosing with BB-10901 followed by a phase II efficacy expansion ImmunoGen, Inc $13,965
Miguel Villalona OSU 05046: Phase 2 study of the anti-angiogenesis agent AG-013736 as second-line treatment in patients with advanced non-small cell lung cancer Parexel Intl Corp $0
Miguel Villalona OSU0486: Phase I dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of KOS-1584 in patients with advanced solid tumors Kosan Biosciences Inc $184,599
Miguel Villalona Study of capecitabine and docetaxel in previously treated non-small cell lung cancer patients. Roche Labs, Inc $53,900
Miguel Villalona Thalidomide and Cox-2 inhibition as a modulator of irinotecan's anticancer activity. Celgene Corp $25,000
Susan Whitman FLT3 genotypes in acute myeloid leukemia. Nat Cancer Inst $140,966
Yiqing Xu OSU 0436: Safety and efficacy of PANVAC(TM) -VF in combination with GM-CSF versus best supportive care or palliative chemotherapy in patients with metastatic adenocarcinoma of the pancreas who have failed a gemcitabine-containing chemotherapy regimen Therion Biologics Corp $0

Division of Human Genetics

Charis Eng Genetics of PTEN and molecular-based patient care. Doris Duke Charitable Fdn $668,817

Division of Immunology

Clark Anderson FcRn binds and transports albumin Nat Inst of Allergy &Infectious Diseases $317,688
Clark Anderson How FcRn prolongs IgG lifespan. Nat Cancer Inst $244,850
Kevin Hackshaw A phase III study to investigate the efficacy and safety of GW406381 1 mg, 5 mg, 10 mg, 25 mg and 50 mg administered once daily, in adults with osteoarthritis of the knee GlaxoSmithKline $2,500
Kevin Hackshaw Abatacept in rheumatoid arthritis Bristol-Myers Squibb Co $7,564
Kevin Hackshaw Efficacy and safety of GW406381, 5 mg, 10 mg, 25 mg, and 50 mg administered orally once daily in adults with rheumatoid arthritis GlaxoSmithKline $6,652
Kevin Hackshaw Humira efficacy response optimization study in subjects with active rhumatoid arthritis Abbott Labs $2,000
Seth Kantor Raloxifene alendronate comparison in postmenopausal women with low bone mass. Eli Lilly & Co $5,245

Division of Infectious Diseases

Susan Koletar Adult AIDS clinical trials unit. Nat Inst of Allergy &Infectious Diseases $1,980,025
Susan Koletar Chair, site evaluation subcommittee (SES) of the adult executive committee for the adult AIDS clinical trials group SOCIAL & SCIENTIFIC SYSTEMS, INC $28,572
Susan Koletar Family-centered, community-based, coordinated HIV care program (FACES). Childrens Res Inst (Columbus) $77,673
Susan Koletar Study of the efficacy of subcutaneous recombinant, human interleukin-2 in HIV-infected patients with low CD4+ counts under active antiretroviral therapy (SILCAAT). Chiron Corp $6,800
Julie Mangino A phase 3, randomized, double-blind, comparative study of micafungin (FK463) versus caspofungin as antifungal treatment in patients with invasive candidiasis or candidemia Fujisawa Healthcare Inc $21,385
Bradford McGwire Characterization of the surface metalloproteases of Trypanosoma cruzi Am Heart Assn-Ohio Affiliate Inc $60,500
Michael Para A phase 1, randomized, placebo-controlled, single injection, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CCR5mAb004 in HIV-1 seropositive individuals who are not receiving concurrent... Human Genome Sci's Inc $11,061
Michael Para A phase 3, randomized, open-label, multicenter study of the treatment of antiretroviral-naive, HIV-1-infected subjects comparing tenofovir disoproxil fumarate and emtricitabine in combination with efavirenz versus Combivir(R) and efavirenz. GILEAD SCIENCES, INC. $12,188
Michael Para AIDS education training center Univ of Pittsburgh $5,000
Michael Para Pneumonia cohort study INVERESK RES NC INC $3,950
Michael Para Safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects. Boehringer Ingelheim Pharmaceuticals Inc $5,474
Larry Schlesinger Research to study virulence of Mycobacterium avium complex bacteria from drinking water. Environmental Protection Agency $100,000
Larry Schlesinger TB and innate immune regulation of lung macrophages Nat Inst of Allergy &Infectious Diseases $492,500
Joanne Turner CD8 T cells and immunity to tuberculosis in old mice Nat Inst on Aging $325,952
Joanne Turner In vitro predictors of susceptibility to reactivation tuberculosis. Am Lung Assn $60,000

Division of Nephrology

Anil Agarwal A multicenter, double-blind, randomized, parallel group study to evaluate the effects of lotrel and lotensin HCT on microalbuminuria in mild to moderate hypertensive subjects with type 2 diabetes mellitus. Novartis Pharmaceuticals Corp $19,514
Anil Agarwal A trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension Novartis Pharmaceuticals Corp $42,232
Anil Agarwal An open-label, single-arm study to assess the safety of darbepoetin alfa manufactured by a serum free bioreactor technology in subjects with chronic kidney disease Amgen Inc $0
Anil Agarwal Efficacy and safety of an oral calcimimetic agent when two different vitamin D regimens are used in subjects with secondary hyperparathyroidism of end stage kidney disease. Amgen Inc $833
Anil Agarwal Nabi-1371 A phase 3, multicenter, randomized, placebo-controlled, double-blinded study to evaluate efficacy of StaphVax, a bivalent Staphylococcus aureus glycoconjugate vaccine in adults on hemodialysis. Nabi Biopharmaceuticals $26,077
Anil Agarwal Protocol 20030153. Amgen Inc $12,156
Anil Agarwal Protocol No. 20030237 Amgen Inc $19,919
Lee Hebert A 24-week, randomized, parallel group, multi-center, open-label study of the renal effects of tesaglitazar in patients with type 2 diabetes mellitus (ARMOR) Astrazeneca Lp $44,455
Lee Hebert A phase III study of the safety and efficacy of ferumoxytol (compared with oral iron) as iron replacement therapy in chronic kidney disease patients not on dialysis. Advanced Magnetics, Inc $29,203
Lee Hebert A randomized, double-blind, placebo-controlled, four-arm, parallel-group, multicenter, multinational safety and efficacy trial of 100mg and 300mg of LJP 394 in systemic lupus erythematosus (SLE) patients La Jolla Pharmaceutical Co $10,416
Lee Hebert AASK cohort Lenox Hill Hosp $70,125
Lee Hebert AASK cohort study Nat In Diabetes&Digestive&KidneyDiseases $163,297
Lee Hebert Data audit of Cell-Cept trial Aspreva Pharmaceuticals Corp $11,000
Lee Hebert Efficacy study trial of preventing hypertension using candesartan cilexetil 16mg in patients with high normal blood pressure (TROPHY). Astrazeneca Lp $2,515
Lee Hebert Genetic and clinical risk for human SLE nephritis. Nat In Diabetes&Digestive&KidneyDiseases $974,620
Todd Pesavento A randomized, controlled trial of homocysteine (FAVORIT). Rhode Island Hosp $28,100
Brad Rovin Lupus clinical trials consortium. Lupus Clinical Trials Consortium, Inc $100,000
Ganesh Shidham Comparison of cyclosporine A and mycophenolate in FSGS St Joseph's Hospital & Medical Center $0
Dan Speite A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy St Joseph's Hospital & Medical Center $1,000
Dan Speite Correction of hemoglobin and outcomes in renal insufficiency. Ortho Biotech Prods LP $28,261
Dan Speite Study of heart and renal protection (SHARP). University of Oxford $30,000
Xiaolan Zhang SELDI application in urine proteomic profiling in lupus nephritis Nat Kidney Fdn of Ohio $6,500

Division of Pulmonary, Critical Care and Sleep Medicine

James Allen Jr. A double-blind, placebo-controlled, study of E5564, a lipid A antagonist, administered by twice daily intravenous infusions in patients with severe sepsis. EISAI CO LTD $13,143
James Allen Jr. A prospective, randomized, double-blind, placebo-controlled study of the safety and efficacy of three days continuous intravenous infusion of GR270773 in the treatment of suspected or confirmed gram-negative severe sepsis in adults GlaxoSmithKline $7,529
James Allen Jr. A randomized, double-blind, placebo-controlled, multinational, phase 3 study of the safety and efficacy of 200 ug subcutaneous interferon gamma-1b (IFN-y 1b) in patients with idiopathic pulmonary fibrosis (GIPF-007) Intermune Inc $26,929
James Allen Jr. Venticute (rSP-C surfactant) in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment (VALID study), BY2001/M1-007. ALTANA, INC. $11,066
Elliott Crouser Induction of inflammation by mitochondrial proteins Nat Inst of Allergy &Infectious Diseases $74,750
Elliott Crouser Stromal gene expression during pulmonary sarcoidosis Nat Heart, Lung, & Blood Inst $224,250
Philip Diaz Alveolar macrophage proteomics in HIV-induced emphysema Nat Heart, Lung, & Blood Inst $390,569
Philip Diaz Clinical center for the National Emphysema Treatment Trial (NETT) Nat Heart, Lung, & Blood Inst $31,045
Philip Diaz Pilot study of the Spiration IBV valve system Spiration, Inc $0
Stephen Hoffmann Efficacy and safety of drotrecogin alfa (activated) in adult patients with early stage severe sepsis. Eli Lilly & Co $1,700
Rami Khayat Performance of CPAP and bi-Flex in treating SDB in a heart failure population Respironics, Inc $0
Valery Khramtsov In vivo imaging and spectroscopy of pH and thiols status Nat In Biomedical Imaging&Bioengineering $153,150
John Mastronarde Asthma clinical research center Am Lung Assn $134,562
John Mastronarde Exercise as an anti-inflammatory therapy for asthma Nat Center for Research Resources $118,677
John Mastronarde Leukotrine modifiers or corticosteroids trial (LOCS) Childrens Res Inst (Columbus) $18,375
John Mastronarde Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus Omnicare Clinical Res Inc $6,688
James O'Brien A double-blind, placebo-controlled, parallel group phase II dose-ranging study of nebulized Amikacin delivered via the pulmonary drug delivery system (PDDS) in patients with ventilator-associated pneumonia due to gram-negative organisms PPD Dev $0
James O'Brien The obese critical III: Process and outcome disparities Nat Heart, Lung, & Blood Inst $130,248
Ruaidhri Ofathaigh Fibroproliferative ARDS: Mechanisms of cell death and repair Nat Heart, Lung, & Blood Inst $129,060
Jonathan Parsons Exercise-induced bronchoconstriction in college athletes using eucapnic voluntary hyperventilation as a bronchoprovocation technique: Prevalence, markers of inflammation, and quality of life The CHEST Fdn $10,000
Susheela Tridandapani SHIP-2 influence on macrophage Fc receptor function Nat Inst of Allergy &Infectious Diseases $239,200
Mark Wewers Macrophage inflammasome regulation Nat Heart, Lung, & Blood Inst $299,000
Mark Wewers Regulation of macrophage interleukin-1 beta production Nat Heart, Lung, & Blood Inst $206,500
Karen Wood Alloimmunity and lung disease after bone marrow transplantation Am Lung Assn $40,000
Karen Wood Lung alloimmunity after bone marrow transplantation Nat Heart, Lung, & Blood Inst $130,518

Department of Molecular & Cellular Biochemistry

Charles Bell Structural studies of RecA-DNA complexes. Nat Inst Gen Medical Scis $258,125
Arthur Burghes Does SMA result from defects in motor neuron development in the mouse? Families of Spinal Muscular Atrophy $104,407
Arthur Burghes Protective effects of butyrate analogues and prodrugs on a mouse model of SMA Families of Spinal Muscular Atrophy $104,407
Arthur Burghes Survival motor neuron genes in spinal muscular atrophy. Nat Inst Neurological Disorders & Stroke $343,040
Arthur Burghes Testing of MediChem (deCODE)(FSMA) compounds for induction of SMN expression from SMN2 Families of Spinal Muscular Atrophy $104,000
Tsonwin Hai ATF3 in beta cell signaling, gene expression and destruction. Nat In Diabetes&Digestive&KidneyDiseases $285,783
Tsonwin Hai Beta cell transcriptional network in stress response Am Diabetes Assn Inc $100,000
Russell Hille Structure/activity studies of two molybdenum enzymes Nat Inst Gen Medical Scis $252,000
Russell Hille Studies of environmentally relevant molybdenum enzymes Nat Inst of Environ Health Scis $343,306
Samson Jacob Molecular mechanisms of diet-induced carcinogenesis. Nat Cancer Inst $295,369
Jeffrey Kuret Structure and genesis of tau filaments Nat Inst on Aging $275,828
Jeffrey Kuret Structure and genesis of tau filaments. Nat Inst on Aging $129,788
Jeffrey Kuret Triggers and enhancers of tau filament formation Alzheimer's Assn $80,000
Jiyan Ma The pathogenic mechanism of prion disease. ELLISON MEDICAL FOUNDATION $50,000
Jiyan Ma The role of ubiquitinated prion protein in neurodegeneration AM FEDERATION FOR AGING RESEARCH INC $149,000
Kamal Mehta Role of protein kinase Cbeta in diet-induced hypercholesterol mice. Nat Heart, Lung, & Blood Inst $239,200
Mark Parthun Characterization of type B histone acetyltransferases Nat Inst Gen Medical Scis $244,850
Mark Parthun Chromatin regulation as a therapeutic target to enhance biologic therapies in CLL V Fdn $180,000
Douglas Pfeiffer Manipulation of lead using carboxylic acid ionophores. Nat Inst Gen Medical Scis $244,830
Douglas Pfeiffer Mitochondrial dysfunction in disease of the eye. Alcon Labs Inc $40,000
Douglas Pfeiffer Targeting the mitochondrial calcium uniporter, Phase I Nat Inst Gen Medical Scis $112,125
Jill Rafael-Fortney DLG and CASK at the mammalian neuromuscular junction. Nat In Arthritis&Muscoskeletal&Skin Ds $323,944
Jill Rafael-Fortney Localization and protein association of dystrophin, utrophin, and PDZ domain proteins in the heart in normal and cardiomyopathic mouse models. American Heart Association $75,000
Daniel Schoenberg Beta-globin mRNA decay in erythroid cells. Nat Institutes of Health $149,500
Daniel Schoenberg Hormonal regulation of mRNA stability Nat Inst Gen Medical Scis $371,213
Said Sif The role of histone methylase containing human SW/SWF complexes in cancer. Am Cancer Soc Inc $536,332
Scott Walsh Structure and energetic studies of interleukins and receptors American Heart Association $65,000
Sung Ok Yoon Mechanisms of crosstalk between NGF receptors, TrkA and p75. Nat Inst Neurological Disorders & Stroke $345,719
Sung Ok Yoon Proneurotrophin actions in acute spinal cord injury Cornell Univ $125,000
Sung Ok Yoon Role of p75 as the receptor regulating pro-apoptotic JNK3 and Rho activity after spinal cord injury. Christopher Reeve Paralysis Fdn $75,000

Department of Molecular Virology, Immunology and Medical Genetics

George Calin The role of microRNAs in human cancer development Sidney Kimmel Fdn Cancer Res $150,000
Carlo Croce 8p22 alterations in prostate, breast and esophageal CA Nat Cancer Inst $338,483
Carlo Croce Molecular basis of CLL Univ of California at San Diego $295,880
Carlo Croce Oncogene in cancer etiology and progression Nat Cancer Inst $362,667
Carlo Croce Role of Fhit in apoptosis and susceptibility to therapy Thomas Jefferson Univ $346,880
Carlo Croce The microRNA genes in hematopoietic/mesenchimal/neural development and neoplasias Fondazione Adrioano Buzzati-Traverso $300,000
Albert de la Chapelle BAALC in neurogenesis and hematopoiesis. Nat Cancer Inst $306,475
Albert de la Chapelle Postdoctoral training in cancer genetics. Nat Cancer Inst $226,501
Rami Eqilan The role of WWOX tumor suppressor gene in cancer Sidney Kimmel Fdn Cancer Res $200,000
Richard Fishel A mechanism-based screen ... and human cells in vitro Strang Cancer Prevention Ctr $388,162
Richard Fishel Functional studies of the meiotic MutS homologs hMSH4-hMSH5 Nat Inst Gen Medical Scis $263,120
Richard Fishel Human mismatch repair proteins and carcinogenesis Nat Cancer Inst $363,998
Richard Fishel Recombination/repair complex in human cells Nat Cancer Inst $357,803
M Ronald Glaser Stress, the immune system and basal cell carcinoma Nat Cancer Inst $760,303
John Gunn An oral vaccine against multiple biowarfare agents The Univ of Texas at San Antonio $92,859
John Gunn Development of a single oral vaccine against multiple food-borne pathogens UNIV OF TEXAS HLTH SCI CTR - SAN ANTONIO $21,339
John Gunn Salmonella antimicrobial peptide resistance. Nat Institutes of Health $538,200
John Gunn Tularemia pathogenesis and host response (RCE) The Univ of Texas at San Antonio $59,247
Denis Guttridge Cytokines and NF-kappaBeta regulation of cancer cachexia. Nat Cancer Inst $153,208
Denis Guttridge Modulation of skeletal muscle protein degradation with natural compounds in experimental cancer cachexia models. Ross Products Div $25,000
Denis Guttridge NF-kB regulation of muscle wasting in cancer cachexia. Nat Cancer Inst $245,219
Tim Hui-Ming Huang DNA hypermethylation in breast cancer. Nat Cancer Inst $262,550
Tim Hui-Ming Huang Epigenetic biomarkers for ovarian cancer progression. Nat Cancer Inst $249,267
Tim Hui-Ming Huang Interrogating epigentic changes in cancer genomes. Nat Cancer Inst $2,862,114
Tim Hui-Ming Huang Novel tool for analysis of promoter hypermethylation. Nat Cancer Inst $378,836
Tim Hui-Ming Huang Reactivation of methylation-silenced genes by polyphenols Rutgers Univ $131,858
Frances Huebner Role of the FHIT locus in environmental carcinogenesis Nat Cancer Inst $278,873
Frances Huebner The WWOX signaling pathway CYTOGEN Corp $0
Kimberly Kelly Survey of PCP's comfort with management of HBOC and HNPCC Univ of Kentucky $34,633
Ricky Kittles Construction and application of a U.S. admixture map Pennsylvania State Univ $128,071
Gustavo Leone Cell cycle control in the developing placenta. March Dimes Birth Defects Fdn $75,407
Gustavo Leone E2F3 and embryonic development Nat Inst Child Health & HumanDevelopment $322,375
Gustavo Leone E2F3 gene locus in the control of cell proliferation. Nat Cancer Inst $232,313
Gustavo Leone The role of e2f3 in breast cancer Susan G Komen Breast Cancer Fdn $45,000
Michael Ostrowski Genetic analysis of the breast tumor microenvironment Nat Cancer Inst $1,327,136
Michael Ostrowski Mi: Modulating osteoclast gene expression and function. Nat In Arthritis&Muscoskeletal&Skin Ds $158,083